Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Rhea-AI Summary

Silo Pharma (NASDAQ: SILO) highlighted its lead intranasal PTSD candidate, SPC-15, and said it is positioned to benefit from renewed federal focus on psychedelic-based therapies following an April 18, 2026 executive order directing agencies to accelerate research.

SPC-15 is a 5-HT4 receptor agonist delivered intranasally via a nose-to-brain device, advanced under a 505(b)(2) regulatory pathway, backed by Columbia University-licensed IP, and preparing for IND engagement with the FDA.

Argus Apr 20 session

+29.34% close to close Open Argus

Details

News Market Reaction – SILO

On Apr 20, the day this news came out, SILO closed 29.34% above the previous close.

Data tracked by StockTitan Argus for the Apr 20 session.

Key Figures

Regulatory pathway: 505(b)(2)

Regulatory pathway

505(b)(2)

SPC-15 intranasal PTSD program development route

Historical Context

5 past events · Latest: Apr 06

5 events

1. Apr 06

   European patent allowance

   24h Move

   +49.0%

   European allowance expanding SPC-15 prophylactic PTSD IP protection.

2. Feb 23

   Share buyback authorization

   24h Move

   +24.0%

   Board-approved repurchase program of up to $1,000,000 in common stock.

3. Feb 18

   Japan patent allowance

   24h Move

   -3.2%

   Notice of Allowance in Japan for SPC-15 intranasal PTSD patent.

4. Dec 30

   Phase 1 LOI

   24h Move

   +4.7%

   LOI with Allucent to support two Phase 1 SPC-15 SAD and MAD studies.

5. Nov 17

   Allucent partnership

   24h Move

   -1.1%

   Partnership with Allucent for planned 2026 FDA IND preparation for SPC-15.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

post-traumatic stress disorder, ptsd, 505(b)(2) regulatory pathway, intranasal, +3 more

7 terms

post-traumatic stress disorder medical

"psychedelic-based treatments for mental health disorders. Recent ... post-traumatic stress disorder (PTSD), depression"

A mental health condition that can develop after a person experiences or witnesses a traumatic event, causing persistent symptoms such as intrusive memories, heightened stress reactions, avoidance of reminders, and trouble sleeping or concentrating. For investors it matters because it can reduce employee productivity, increase healthcare and disability costs, alter consumer behavior, and create demand for treatment and support services—think of a business whose systems keep freezing after a shock, requiring ongoing fixes and higher operating costs.

ptsd medical

"psychedelic compounds for medical use—particularly in areas such as post-traumatic stress disorder (PTSD), depression"

PTSD, or post-traumatic stress disorder, is a mental health condition that can develop after experiencing or witnessing a traumatic event, leading to ongoing feelings of fear, anxiety, or distress. For investors, understanding PTSD is important because widespread psychological impacts can influence market behavior, cause sudden shifts in confidence, or affect economic stability during times of collective trauma or crisis.

505(b)(2) regulatory pathway regulatory

"The program is being advanced under a 505(b)(2) regulatory pathway, potentially enabling a streamlined"

A 505(b)(2) regulatory pathway is a U.S. drug approval route that allows a company to use some existing safety and effectiveness data from earlier studies or other approved products instead of repeating every test. It speeds development and cuts costs compared with a full new-drug filing while still requiring new data for any changes. For investors, it can shorten time to market and reduce development risk—think of renovating a house using an existing foundation rather than building from scratch.

intranasal medical

"SPC-15, is an intranasal prophylactic treatment targeting PTSD, designed to leverage rapid"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

serotonin 4 (5-HT4) receptor agonist medical

"Designed as a novel serotonin 4 (5-HT4) receptor agonistTargeting prophylactic treatment of PTSD"

A serotonin 4 (5-HT4) receptor agonist is a drug that binds to and activates a specific protein on cells called the 5-HT4 receptor, which helps regulate things like gut movement, fluid secretion, and certain brain signals. For investors, these drugs matter because they can address unmet medical needs (for example, digestive or some brain disorders) and their commercial value depends heavily on clinical trial results, safety profile and regulatory approval—think of it as turning a biological switch that may unlock a new treatment market.

cns medical

"Focus on nose-to-brain delivery platforms, a rapidly emerging segment in CNS therapeutics Market Opportunity"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

nose-to-brain delivery medical

"SPC-15, is an intranasal prophylactic treatment ... designed to leverage rapid nose-to-brain delivery"

Nose-to-brain delivery is a method of getting medicines from the nasal passages directly into the brain by using pathways that bypass the bloodstream’s main barrier to the brain. Think of it as a short-cut route that can speed up effect, reduce required dose, and avoid some side effects. Investors care because this approach can change the safety, cost, patent value, and market potential of treatments for brain conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies

SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders.

Recent national media coverage has underscored growing momentum at the federal level to evaluate reforms related to psychedelic compounds for medical use—particularly in areas such as post-traumatic stress disorder (PTSD), depression, and anxiety. On Saturday, April 18, 2026, President Trump signed an executive order directing multiple U.S. government agencies to accelerate research into psychedelic therapies and patient access.

Silo Pharma’s lead program, SPC-15, is an intranasal prophylactic treatment targeting PTSD, designed to leverage rapid nose-to-brain delivery for enhanced therapeutic effect and patient compliance. The program is being advanced under a 505(b)(2) regulatory pathway, potentially enabling a streamlined development timeline.

“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions,” said Eric Weisblum, CEO of Silo Pharma. “We believe Silo is well positioned with SPC-15 and it broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment.”

Key Highlights of SPC-15 (PTSD Program):

• Designed as a novel serotonin 4 (5-HT4) receptor agonist
  
  
• Targeting prophylactic treatment of PTSD and stress-induced disorders
  
  
• Administered via an intranasal formulation designed for rapid CNS delivery
  
  
• Backed by intellectual property licensed from Columbia University
  
  
• Preparing for IND engagement with the FDA
  
  
• Advanced drug delivery strategy
  
  
• Partnership for optimized intranasal device development
  
  
• Focus on nose-to-brain delivery platforms, a rapidly emerging segment in CNS therapeutics

Market Opportunity

The global mental health therapeutics market continues to expand, with PTSD alone affecting millions of individuals annually. Openness to psychedelic-assisted and psychedelic-derived therapies may unlock significant new treatment paradigms and commercial opportunities.

Silo Pharma believes that evolving regulatory frameworks could accelerate innovation across the sector, particularly for companies with clinically grounded, delivery-optimized, and IP-backed approaches.

About Silo Pharma, Inc.

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. For more information, please visit silopharma.com.

Forward Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at https://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact
investors@silopharma.com
(800) 705-0120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Silo Pharma announcing about SPC-15 and PTSD on April 20, 2026 (SILO)?

Silo Pharma is positioning SPC-15 as an intranasal prophylactic targeting PTSD with nose-to-brain delivery. According to the company, SPC-15 is a 5-HT4 receptor agonist advanced under a 505(b)(2) pathway and backed by Columbia University-licensed intellectual property.

How might the April 18, 2026 executive order affect Silo Pharma (SILO) development plans?

The executive order may accelerate federal research and regulatory attention to psychedelic therapies, potentially benefiting developers like Silo. According to the company, the order directs agencies to speed psychedelic research and patient access, which could influence regulatory environment and clinical pathways.

What regulatory pathway is Silo Pharma using for SPC-15 (SILO) and why does it matter?

Silo Pharma is advancing SPC-15 under a 505(b)(2) regulatory pathway to potentially streamline development and rely on existing data. According to the company, this pathway may enable an abbreviated program compared with full de novo approaches, subject to FDA engagement and review.

What is the delivery strategy for SPC-15 and its potential investor significance for SILO?

SPC-15 uses an intranasal nose-to-brain delivery approach intended for rapid CNS access and patient compliance. According to the company, the device partnership and delivery optimization aim to differentiate the program in CNS therapeutics and support clinical development.

Has Silo Pharma secured intellectual property for SPC-15 (SILO)?

Yes. According to the company, SPC-15 is backed by intellectual property licensed from Columbia University. The company cites the licensed IP as supportive of its development and potential commercialization strategy for the intranasal PTSD program.

What are the next development steps for SPC-15 as announced by Silo Pharma (SILO)?

Silo Pharma is preparing for IND engagement with the FDA and continuing device optimization for intranasal delivery. According to the company, these steps aim to advance SPC-15 toward clinical study initiation under a 505(b)(2) pathway, pending regulatory feedback.